grant

Leveraging Biologically Specific PET/MRI Monitoring and Therapeutic Modulation of the Hypoxic Glioblastoma Tumor Immune Microenvironment into Improved Outcomes

Organization OREGON HEALTH & SCIENCE UNIVERSITYLocation PORTLAND, UNITED STATESPosted 1 May 2024Deadline 30 Apr 2029
NIHUS FederalResearch GrantFY202621+ years oldAccelerationAddressAdultAdult HumanAstrocytesAstrocytusAstrogliaBiologicalBiological MonitoringBiologyBlood VesselsBrainBrain CancerBrain NeoplasiaBrain NeoplasmsBrain Nervous SystemBrain TumorsCancer TreatmentCancersCell Growth in NumberCell MultiplicationCell ProliferationCellular ProliferationClinicalClinical TreatmentClinical TrialsDataDevelopmentDiagnosisDiagnosticEarly InterventionEncephalonFDA approvedFailureFe elementFerahemeFutureGadoliniumGd elementGeneralized GrowthGlioblastomaGoalsGrade IV Astrocytic NeoplasmGrade IV Astrocytic TumorGrade IV AstrocytomaGrowthHeterograftHeterologous TransplantationHortega cellHumanHypoxiaHypoxicHypoxic tumorImageImaging technologyImmune mediated therapyImmunologically Directed TherapyImmunosuppressionImmunosuppression EffectImmunosuppressive EffectImmunotherapeutic agentImmunotherapyIronKnowledgeLegal patentLinkLytotoxicityMR ImagingMR TomographyMRIMRIsMagnetic Resonance ImagingMalignant Neoplasm TherapyMalignant Neoplasm TreatmentMalignant NeoplasmsMalignant TumorMalignant Tumor of the BrainMalignant neoplasm of brainMeasuresMedical Imaging, Magnetic Resonance / Nuclear Magnetic ResonanceMethodologyMethodsMicrogliaMissionModelingModern ManMonitorNMR ImagingNMR TomographyNational Institutes of HealthNewly DiagnosedNuclear Magnetic Resonance ImagingOperative ProceduresOperative Surgical ProceduresOutcomeOxygen DeficiencyPDX modelPETPET ScanPET imagingPETSCANPETTPatentsPatient derived xenograftPatient outcomePatient-Centered OutcomesPatient-Focused OutcomesPatientsPhase 2 Clinical TrialsPhase II Clinical TrialsPlayPositron Emission Tomography Medical ImagingPositron Emission Tomography ScanPositron-Emission TomographyPre-Clinical ModelPreclinical ModelsPublic HealthRad.-PETResearchResistanceResistance developmentResistant developmentRodentRodent ModelRodentiaRodents MammalsScheduleSurgicalSurgical InterventionsSurgical ProcedureTechniquesTemodalTemodarTestingTherapeuticTimeTissue GrowthTreatment EfficacyTreatment outcomeTumor EscapeTumor Immune EscapeTumor-associated macrophagesUnited States National Institutes of HealthXenograftXenograft procedureXenotransplantationZeugmatographyadulthoodangiogenesisanti-cancer immunotherapyanti-cancer therapyanticancer immunotherapyastrocytic gliabiologicbiomonitoringcancer evasioncancer immune escapecancer immune evasioncancer immunotherapycancer therapycancer typecancer-directed therapycheck point immunotherapycheck point inhibitor therapycheck point inhibitory therapycheck point therapycheckpoint immunotherapycheckpoint inhibitor therapycheckpoint inhibitory therapycheckpoint therapychemo-/radio-therapychemo-radiotherapychemoradiationchemoradiation therapychemoradiation treatmentchemoradiotherapyclinical developmentclinical efficacyclinical interventionclinical therapyclinical validationcohortcytotoxiccytotoxicitydeveloping resistancedevelopmentaldiagnostic abilitydiagnostic capabilitydiagnostic powerdiagnostic utilitydiagnostic valuedisabilityevidence baseferumoxytolfunctional statusgitter cellglioblastoma multiformeimagingimmune check point therapyimmune checkpoint therapyimmune drugsimmune microenvironmentimmune suppressionimmune suppressive activityimmune suppressive functionimmune therapeutic approachimmune therapeutic interventionsimmune therapeutic regimensimmune therapeutic strategyimmune therapyimmune-based cancer therapiesimmune-based therapeuticsimmune-based therapiesimmune-based treatmentsimmuno therapyimmunologic therapeuticsimmunosuppressive activityimmunosuppressive functionimmunosuppressive microenvironmentimmunosuppressive responseimmunosuppressive tumor microenvironmentimmunotherapeuticsimmunotherapy agentimmunotherapy for cancerimmunotherapy of cancerimprovedimproved outcomeinnovateinnovationinnovativeintervention efficacymalignancymesogliamethazolastonemicroglial cellmicrogliocytenano particlenano-sized particlenanoparticlenanosized particleneoplasm/cancerneural inflammationneuro-vascular unitneuroinflammationneuroinflammatoryneurovascular unitnon-invasive monitornoninvasive monitornovelnovel imaging technologyoff-label applicationoff-label prescribingoff-label useontogenypatient derived xenograft modelpatient oriented outcomesperivascular glial cellphase II protocolpositron emission tomographic (PET) imagingpositron emission tomographic imagingpositron emitting tomographypre-clinicalpreclinicalprognostic performanceprospectiveradio-chemo-therapyradio-chemotherapyradiochemotherapyresistantsegregationspongioblastoma multiformestandard carestandard of carestandard treatmentsurgerytemozolomidetherapeutic agent developmenttherapeutic developmenttherapeutic efficacytherapeutic targettherapy efficacytooltrial regimentrial treatmenttumortumor evasiontumor hypoxiatumor immune evasiontumor immune microenvironmenttumor-immune system interactionstumors in the brainvascularxeno-transplantxeno-transplantation
Sign up free to applyApply link · pipeline · email alerts
— or —

Get email alerts for similar roles

Weekly digest · no password needed · unsubscribe any time

Description preview

ABSTRACT
Leveraging neuroinflammation to improve treatment outcomes for patients with glioblastoma is challenging

because the hypoxic tumor immune microenvironment (TIME), mostly comprised of immuno-suppressive

tumor-associated macrophages (TAMs), remains incompletely quantified and therapeutically modulated. The

long-term goal is to accelerate…

🔒

Full details available on the Agency plan

Unlock the complete grant description, eligibility criteria, contract value, evaluation details and apply link — plus alerts, pipeline tracking, and CSV export.

Start 7-day free trial — $29.99/mo →

Agency Plan

7-day free trial

Unlock procurement & grants

Upgrade to access active tenders from World Bank, UNDP, ADB and more — with email alerts and pipeline tracking.

$29.99 / month

  • 🔔Email alerts for new matching tenders
  • 🗂️Track tenders in your pipeline
  • 💰Filter by contract value
  • 📥Export results to CSV
  • 📌Save searches with one click
Start 7-day free trial →
Leveraging Biologically Specific PET/MRI Monitoring and Therapeutic Modulation of the Hypoxic Glioblastoma Tumor Immune | Dev Procure